相关实验视频
Updated: May 11, 2026

11:06
3D Printing of Preclinical X-ray Computed Tomographic Data Sets
Published on: March 22, 2013
40.5K
三维打印对于儿科口服固体剂型的潜力
Klemen Kreft1, Marina Fanous2, Volker Möckel2
11Lek Pharmaceuticals d.d., a Sandoz Company, 1000 Ljubljana, Slovenia.
Acta pharmaceutica (Zagreb, Croatia)
|May 30, 2024
概括
3D打印为创建个性化儿科药物提供了一个有前途的解决方案,克服了当前剂量方法的局限性. 这项技术使得量身定制的剂量,定制的释放档案,以及提高了口感,提高了儿童的治疗坚持.
科学领域:
- 制药技术 制药技术 制药技术
- 儿科药理学 儿科药理学
- 增材制造 增材制造是一种增材制造.
背景情况:
- 由于发育和药物动力学变异性,儿童药物剂量存在独特的挑战.
- 目前的方法如分片和液体复合缺乏精度和患者接受度.
- 个性化剂量对于优化儿童治疗结果至关重要.
研究的目的:
- 探索3D打印对于个性化儿科药物的潜力.
- 审查适用于制药制造的3D打印技术.
- 讨论将3D打印整合到儿科药物治疗中的战略.
主要方法:
- 审查3D打印技术及其制药应用.
- 分析个性化选择:剂量,释放动力学,形状和口感.
- 建议一个去中心化的制造模式,用于 point-of-care 3D打印.
主要成果:
- 3D打印允许精确的,个性化的儿科剂量和定制的药物释放.
- 通过增强可口性和新型剂型,提高药物坚持的潜力.
- 一个去中心化的模型促进了3D打印药物的临床生产.
结论:
- 3D打印技术对个性化儿科口服药物具有重大前景.
- 解决监管,质量和知识产权方面的挑战对于广泛采用至关重要.
- 需要进一步的研究和开发,才能充分实现3D打印药物在儿科中的临床益处.
相关概念视频
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.

